Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
In eukaryotic cells, cyclin-dependent kinase (CDK) complexes regulate the temporal progression of cells through the cell cycle. Deregulation in the cell cycle is an essential component in the evolution of cancer. Here, we validate CDK1 and CDK2 as potential therapeutic targets using novel selective small-molecule inhibitors of cyclin B1/CDK1 and cyclin E2/CDK2 enzyme complexes (CDKi). Flow cytometry–based methods were developed to assess intracellular retinoblastoma (Rb) phosphorylation to show inhibition of the CDK pathway. Tumor cells treated with CDK inhibitors showed an overall decrease in cell proliferation, accumulation of cells in G1 and G2, and apoptosis in a cell line–specific manner. Although CDK inhibitors activate p53, the inhibitors were equipotent in arresting the cell cycle in isogenic breast and colon tumor cells lacking p53, suggesting the response is independent of p53. In vivo, the CDK inhibitors prevented the growth of colon and prostate tumors, blocked proliferation of tumor cells, and inhibited Rb phosphorylation. The discovery and evaluation of novel potent and selective CDK1 and CDK2 inhibitors will help delineate the role that CDK complexes play in regulating tumorigenesis. (Cancer Res 2006; 66(8): 4299-308)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks
Burma, S., Chen, B. P., Murphy, M., Kurimasa, A., & Chen, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100466200 · Cited by 1,954 · cited 1×
“The phosphorylation of histone H2AX on Ser(139) by ATM occurs in response to double-strand DNA breaks and apoptosismediated genome fragmentation (36, 37).”
BackgroundTargets of the cyclin-dependent kinase Cdk1
Ubersax, J. A., Woodbury, E. L., Quang, P. N., Paraz, M., Blethrow, J. D., Shah, K., Shokat, K. M., & Morgan, D. O. (2003) · Nature · doi:10.1038/nature02062 · Cited by 892
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Cited by
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update
Tadesse, S., Caldon, E. C., Tilley, W., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01469 · Cited by 276
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases
Bettayeb, K., Oumata, N., Echalier, A., Ferandin, Y., Endicott, J. A., Galons, H., & Meijer, L. (2008) · Oncogene · doi:10.1038/onc.2008.191 · Cited by 184
Metadata
- Authors
- Payton, M., Chung, G., Yakowec, P., Wong, A., Powers, D., Xiong, L., Zhang, N., Leal, J., Bush, T. L., Santora, V., Askew, B., Tasker, A., Radinsky, R., Kendall, R., & Coats, S.
- Venue
- Cancer Research
- Published
- 2006-04-15
- Volume
- 66
- Issue
- 8
- Pages
- 4299-4308
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2137898468
- Cited by
- 83
- References
- 3
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-2507
- The paper
- Payton, M., Chung, G., Yakowec, P., Wong, A., Powers, D., Xiong, L., Zhang, N., Leal, J., Bush, T. L., Santora, V., Askew, B., Tasker, A., Radinsky, R., Kendall, R., & Coats, S. (2006). Discovery and Evaluation of Dual CDK1 and CDK2 Inhibitors. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-2507
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.